The following is a summary of share-based compensation expenses reported in the consolidated condensed statements of operations and comprehensive loss for the three and six months ended June 30, 2026 and 2025:

	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2026		2025		2026		2025
Research and Development	$	29,368	$	-	$	29,828	$	-
General and Administrative Expenses		69,037		78,620		192,679		265,383
Total Share-Based Compensation Expense Included in Operating Expenses	$	98,405	$	78,620	$	222,507	$	265,383

On November 22, 2022, the Company adopted the 2022 Equity Incentive Plan (the “2022 Plan”), which provides for the grant of stock options, stock appreciation rights, restricted stock, restricted stock units and performance awards to eligible employees, directors and consultants, to be granted from time to time by the Board of Directors of the Company. To date, the Company has granted shares of common stock, restricted stock units, stock options to employees, nonemployees, and directors under the 2022 Plan. As of June 30, 2026, the number of remaining shares available for issuance under the 2022 Plan is equal to 87,784.

The Company grants stock options to employees, nonemployees, and directors with exercise prices equal to the closing price of the underlying shares of the Company’s common stock on the Nasdaq Capital Market on the date that the options are granted. Options granted generally have a term of five to ten years from the grant date and are subject to vesting as determined in the individual award agreement. The Company estimates the fair value of stock options on the grant date by applying the Black-Scholes option pricing valuation model.

There were no stock options granted during the three months ended June 30, 2026 and 2025. During the six months ended June 30, 2026 and 2025, Company granted a total of 0 and 30,000 stock options at a weighted average per share exercise price of $0 and $26.20. These options are subject to vesting annually in five equal tranches, with the first 20% tranche fully vested on the date of grant and thereafter, vest on the last date of each fiscal year beginning December 31, 2025. The weighted average grant date fair value of options granted during the six months ended June 30, 2025 was $18.20.

The following table summarizes the significant assumptions used in determining the fair value of options granted during the three and six months ended June 30, 2026 and 2025:

	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2026		2025		2026		2025
Weighted-average grant date fair value		N/A		N/A		N/A	$	18.20
Risk-free interest rate		N/A		N/A		N/A		4.36%
Expected volatility		N/A		N/A		N/A		90.00%
Expected term (years)		N/A		N/A		N/A		4.50
Expected dividend yield		N/A		N/A		N/A		0.00%

For the three months ended June 30, 2026 and 2025, the Company recognized $46,978 and $34,503 of compensation expense related to stock option awards, respectively ($126,502 and $177,148 for the six months ended June 30, 2026 and 2025).

Compensation cost for service-based RSUs is based on the grant date fair value of the award, which is the closing market price of the Company’s common stock on the grant date multiplied by the number of shares awarded.

On March 4, 2026, the Company entered into a consulting agreement with an external consultant to provide strategic advisory services. As consideration for such services, the consultant is entitled to receive equity compensation in the form of shares of the Company’s common stock. These awards are accounted for as nonemployee share-based compensation under ASC 718. Pursuant to the agreement, the Company agreed to grant 20,000 restricted stock units (“RSUs”) that vested in full on the effective date of the agreement, and an additional 2,500 RSUs for each month of service thereafter, provided the agreement remains in effect. The agreement has an initial term of 12 months and may be terminated at the Company’s option upon seven days’ prior notice.

For the three and six months ended June 30, 2026, the Company granted 7,500 and 27,500 RSUs, respectively, under this agreement with a weighted average grant date fair value of $2.10 per share, all of which vested in full on the grant date. The Company recognized stock-based compensation expense of $12,475 and $57,875 related to these vested RSUs during the three and six months ended June 30, 2026, respectively.

For the three and six months ended June 30, 2025, no RSUs were granted or vested, and the Company recognized no stock-based compensation expense related to RSUs.

In 2023, the Company issued shares of common stock as share-based payments to certain vendors in exchange for services to be rendered to the Company in the future. For fully vested, nonforfeitable equity instruments that are granted at the date the Company and a nonemployee enter into an agreement for goods or services, the Company recognizes the fair value of the equity instruments as a prepaid asset on the grant date, as defined in ASC 718. The corresponding cost is expensed over the service period depending on the specific facts and circumstances of the agreement with the nonemployee. As of June 30, 2026, the remaining unamortized balance of prepaid assets related to these share-based payments for which the grant date criteria has been met is $99,533 ($195,887 at December 31, 2025), which is presented as a component of prepaid and other assets on the accompanying consolidated condensed balance sheets. The remaining $99,533 will be recognized as the related research and development services are provided, which the Company estimates will occur within one year.

The agreements with the nonemployees do not include any provisions to claw back the share-based payments in the event of nonperformance by the nonemployees. Subject to applicable federal and state securities laws, the nonemployees can sell the received equity instruments.